Document:

Exhibit 10.5

Exhibit 10.5
EXECUTION VERSION

JOINDER AGREEMENT
This Joinder Agreement is dated as of September 11, 2012 (this "Agreement"), by and among each of the financial institutions set forth on Schedule A annexed hereto (each a "New Revolving Loan Lender" and collectively the "New Revolving Loan Lenders"), Valeant Pharmaceuticals International, Inc., a corporation continued under the federal laws of Canada ("Borrower"), the undersigned subsidiaries of Borrower and Goldman Sachs Lending Partners LLC ("GSLP"), as Administrative Agent and Collateral Agent.
RECITALS:
WHEREAS, reference is hereby made to the Third Amended and Restated Credit and Guaranty Agreement, dated as of February 13, 2012, as amended by Amendment No. 1, dated as of March 6, 2012, by Amendment No. 2, dated as of September 10, 2012, by the Joinder Agreement, dated as of June 14, 2012, and by the Joinder Agreement, dated as of July 9, 2012 (as it may be amended, restated, replaced, supplemented or otherwise modified from time to time, the "Credit Agreement"; the terms defined therein and not otherwise defined herein being used herein as therein defined), among Borrower, certain Subsidiaries of Borrower, as Guarantors, the Lenders party thereto from time to time, GSLP, J.P. Morgan Securities LLC and Morgan Stanley Senior Funding, Inc. ("Morgan Stanley"), as Joint Lead Arrangers and Joint Bookrunners, JPMorgan Chase Bank, N.A. ("JPMorgan") and Morgan Stanley, as Co-Syndication Agents, JPMorgan, as Issuing Bank, GSLP, as Administrative Agent and Collateral Agent, and the other Agents party thereto; 
WHEREAS, subject to the terms and conditions of the Credit Agreement, Borrower  may obtain New Revolving Loan Commitments and/or New Term Loan Commitments by entering into one or more Joinder Agreements with the New Revolving Loan Lenders; and
WHEREAS, pursuant to Section 2.25 of the Credit Agreement, the Credit Agreement may, without the consent of any other Lenders, be amended as may be necessary or appropriate, in the opinion of the Administrative Agent, to give effect to the provisions of Section 2.25 of the Credit Agreement.
NOW, THEREFORE, in consideration of the premises and agreements, provisions and covenants herein contained, the parties hereto agree as follows:
Each New Revolving Loan Lender (i) confirms that it has received a copy of the Credit Agreement and the other Credit Documents, together with copies of the financial statements referred to therein and such other documents and information as it has deemed appropriate to make its own credit analysis and decision to enter into this Agreement; (ii) agrees that it will, independently and without reliance upon the Administrative Agent or any other Lender or Agent and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under the Credit Agreement; (iii) appoints and authorizes Administrative Agent and each other Agent to take such action as agent on its behalf and to exercise such powers under the Credit Agreement and the other Credit Documents as are delegated to Administrative Agent or such other Agent, as the case may be, by the terms thereof, together with such powers as are reasonably incidental thereto; and (iv) agrees that it will perform in accordance with their terms all of the obligations which by the terms of the Credit Agreement are required to be performed by it as a Lender.

Each New Revolving Loan Lender hereby commits to provide its respective New Revolving Loan Commitment as set forth on Schedule A annexed hereto, on the terms and subject to the conditions set forth below:
		
	1.
	New Revolving Loan Commitments.  The New Revolving Loan Commitments established under this Joinder Agreement shall have identical terms to the Revolving Loan Commitments in existence under the Credit Agreement prior to the date hereof (the "New Revolving Loan Commitment Effective Date").  The New Revolving Loan Commitments and New Revolving Loans made pursuant thereto shall be subject to the provisions of the Credit Agreement and the other Credit Documents, and shall constitute "Revolving Commitments" and "Revolving Loans", respectively, thereunder.

		
	2.
	Closing Fee.  Borrower agrees to pay on the date hereof to Administrative Agent, for the account of each New Revolving Loan Lender party to this Agreement, as fee compensation for the commitment of such New Revolving Loan Lender's New Revolving Loan Commitments, a closing fee in an amount equal to 1.00% of the aggregate principal amount of such New Revolving Loan Lender's New Revolving Loan Commitments as of the date hereof.

		
	3.
	New Lenders.  Each New Revolving Loan Lender (other than any New Revolving Loan Lender that, immediately prior to the execution of this Agreement, is a "Lender" under the Credit Agreement) acknowledges and agrees that upon its execution of this Agreement its New Revolving Loan Commitments shall be effective and that such New Revolving Loan Lender shall become a "Lender" under, and for all purposes of, the Credit Agreement and the other Credit Documents, and shall be subject to and bound by the terms thereof, and shall perform all the obligations of and shall have all rights of a Lender thereunder.

		
	4.
	Borrower's Certifications.  By its execution of this Agreement, the undersigned officer, to the best of his or her knowledge, and Borrower hereby certify that:

		
	i.
	The representations and warranties contained in the Credit Agreement and the other Credit Documents are true and correct in all material respects on and as of the date hereof to the same extent as though made on and as of the date hereof, except to the extent such representations and warranties specifically relate to an earlier date, in which case such representations and warranties were true and correct in all material respects on and as of such earlier date;

		
	ii.
	No event has occurred and is continuing or would result from the consummation of the transactions contemplated hereby that would constitute a Default or an Event of Default; and

		
	iii.
	Borrower has performed in all material respects all agreements and satisfied all conditions which the Credit Agreement provides shall be performed or satisfied by it on or before the date hereof in connection with the transactions contemplated by this Agreement.

		
	5.
	Borrower Covenants.  By its execution of this Agreement, Borrower hereby covenants that:

		
	i.
	Borrower shall deliver or cause to be delivered the following legal opinions and documents: originally executed copies of the favorable written opinions of (a) Skadden, Arps, Slate, Meagher & Flom LLP, U.S. counsel to the Credit Parties, 

2

(b) Chancery Chambers, special Barbados counsel to the Credit Parties, (c) Norton Rose Canada LLP, special Canadian counsel to the Credit Parties, (d) Baker & McKenzie, special Luxembourg counsel to the Credit Parties, (e) Conyers Dill & Pearman Limited, special Bermuda counsel to the Credit Parties and (f) Arthur Cox, special Ireland counsel to the Credit Parties, together with all other legal opinions and other documents reasonably requested by Administrative Agent in connection with this Agreement; and
		
	ii.
	Set forth on the attached Officers' Certificate are the calculations (in reasonable detail) demonstrating compliance, on a Pro Forma Basis after giving effect to the New Revolving Loan Commitments, with the financial tests described in Section 6.7 of the Credit Agreement as of the last day of the most recently ended Fiscal Quarter after giving effect to such New Revolving Loan Commitments.

		
	6.
	Eligible Assignee.  By its execution of this Agreement, each New Revolving Loan Lender (other than any New Revolving Loan Lender that, immediately prior to the execution of this Agreement, is a "Lender" under the Credit Agreement) represents and warrants that it is an Eligible Assignee.

		
	7.
	Notice.  For purposes of the Credit Agreement, the initial notice address of each New Revolving Loan Lender shall be as set forth below its signature below.

		
	8.
	Non-U.S. Lenders.  For each New Revolving Loan Lender that is a Non-U.S. Lender, delivered herewith to Administrative Agent are such forms, certificates or other evidence with respect to United States federal income tax withholding matters as such New Revolving Loan Lender may be required to deliver to Administrative Agent pursuant to subsection 2.20(d) of the Credit Agreement. 

		
	9.
	Recordation of the New Loans.  Upon execution and delivery hereof, Administrative Agent will record the New Revolving Loan Commitments made by New Revolving Loan Lenders pursuant hereto in the Register.

		
	10.
	Reaffirmation.

		
	i.
	Each Credit Party hereby expressly acknowledges the terms of this Agreement and reaffirms, as of the date hereof, the covenants and agreements contained in each Credit Document to which it is a party, including, in each case, such covenants and agreements as in effect immediately after giving effect to this Agreement and the transactions contemplated hereby.

		
	ii.
	Each Credit Party, by its signature below, hereby affirms and confirms (a) its obligations under each of the Credit Documents to which it is a party, and (b) the pledge of and/or grant of a security interest or hypothec in its assets as Collateral to secure such Obligations, all as provided in the Collateral Documents as originally executed, and acknowledges and agrees that such guarantee, pledge and/or grant continue in full force and effect in respect of, and to secure, such Obligations under the Credit Agreement and the other Credit Documents.

		
	iii.
	Each Credit Party acknowledges and agrees that each of the Credit Documents in existence as of the date hereof shall be henceforth read and construed in 

3

accordance with and so as to give full force and effect to the ratifications, confirmations, acknowledgements and agreements made herein. 
		
	11.
	Amendment, Modification and Waiver.  This Agreement may not be amended, modified or waived except by an instrument or instruments in writing signed and delivered on behalf of each of the parties hereto.

		
	12.
	Entire Agreement.  This Agreement, the Credit Agreement and  the other Credit Documents constitute the entire agreement among the parties with respect to the subject matter hereof and thereof and supersede all other prior agreements and understandings, both written and verbal, among the parties or any of them with respect to the subject matter hereof.  It is understood and agreed that each reference in each Credit Document to the Credit Agreement, whether direct or indirect, shall hereafter be deemed to be a reference to the Credit Agreement as amended and supplemented hereby and that this Agreement is a Credit Document.

		
	13.
	GOVERNING LAW.  THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.

		
	14.
	Severability.  Any term or provision of this Agreement which is invalid or unenforceable in any jurisdiction shall, as to that jurisdiction, be ineffective to the extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions of this Agreement or affecting the validity or enforceability of any of the terms or provisions of this Agreement in any other jurisdiction.  If any provision of this Agreement is so broad as to be unenforceable, the provision shall be interpreted to be only so broad as would be enforceable.

		
	15.
	Counterparts.  This Agreement may be executed in counterparts, each of which shall be deemed to be an original, but all of which shall constitute one and the same agreement.

[Remainder of page intentionally left blank]

4

IN WITNESS WHEREOF, each of the undersigned has caused its duly authorized officer to execute and deliver this Agreement as of the date first written above.
GOLDMAN SACHS LENDING PARTNERS LLC, as a "New Revolving Loan Lender"
By:          /s/ Rebecca Kratz     
            Authorized Signatory
Notice Address: 
200 West Street 
New York, NY 10282
Attention: Michelle Latzoni 
Telephone: (212) 934-3921 
Facsimile: (646) 769-7700
CITIBANK, N.A. as a "New Revolving Loan Lender"
		
	By:  
	/s/ Laura Fogarty     
Name:    Laura Fogarty 
Title:    Vice President

Notice Address: 
388 Greenwich Street, Floor 32 
New York, NY 10013
Attention: Laura Fogarty 
Telephone: (212) 816-2197 
Facsimile: (646) 862-8137

[Signature Page to Joinder Agreement]

DBS BANK LTD., LOS ANGELES AGENCY as a "New Revolving Loan Lender"
		
	By:  
	/s/ Aik Lim Kok     
Name:    Aik Lim Kok 
Title:    Assistant General Manager

Notice Address: 
725 South Figueroa Street Suite 2000 
Los Angeles, CA 90017
Attention: General Manager 
Telephone: (212) 627-0222 
Facsimile: (213) 627-0228
SUNTRUST BANK as a "New Revolving Loan Lender"
		
	By:  
	/s/ Dana Dhaliwal     
Name:    Dana Dhaliwal 
Title:    Director

Notice Address: 
3333 Peachtree Road, NE 
7th Floor 
Atlanta, GA 30326
Attention: Valeant Portfolio Manager 
Telephone: (404) 926-5068 
Facsimile: (404) 926-5173

[Signature Page to Joinder Agreement]

BANK OF AMERICA, N.A. as a "New Revolving Loan Lender"
		
	By:  
	/s/ Robert LaPorte     
Name:    Robert LaPorte 
Title:    Vice President 

Notice Address: 
NC1-007-17-11 
100 North Tryon Street 
Charlotte, NC 28255
Attention: Robert LaPorte 
Telephone: (980) 387-1282 
Facsimile: (404) 720-1599

[Signature Page to Joinder Agreement]

MORGAN STANLEY BANK, N.A. as a "New Revolving Loan Lender"
		
	By:  
	/s/ Kelly Chin     
Name:    Kelly Chin 
Title:    Authorized Signatory

Notice Address: 
Edward Henley 
1300 Thames Street, Thames Street Wharf 
Baltimore, MD 21231
Attention: Documentation Team 
Telephone: (443) 627-4326 
Facsimile: docs4loans@ms.com; ms4loands@ms.com 
BARCLAYS BANK PLC as a "New Revolving Loan Lender"
		
	By:  
	/s/ Jeremy Hazan     
Name:    Jeremy Hazan 
Title:    Director

THE BANK OF NOVA SCOTIA as a "New Revolving Loan Lender"
		
	By:  
	/s/ James Rhee     
Name:    James Rhee 
Title:    Managing Director

		
	By:  
	/s/ Christina Brennan     
Name:    Christina Brennan 
Title:    Associate

Notice Address: 
40 King Street West, 62nd Floor 
Toronto, Ontario 
M5W 2X6
Attention: James Rhee, Managing Director 
Telephone: (416) 866-6206 
Facsimile: (416) 866-2010

[Signature Page to Joinder Agreement]

DNB BANK ASA (f/k/a DNB NOR BANK ASA), as a "New Revolving Loan Lender"
		
	By:  
	/s/ Thomas Tangen     
Name:    Thomas Tangen 
Title:    Senior Vice President

		
	By:  
	/s/ Geshu Sugandh     
Name:    Geshu Sugandh 
Title:    Vice President

Notice Address: 
200 Park Avenue, 31st Floor 
New York, NY 10166
Attention:  Theresa Rosu 
Telephone: (212) 681-3845
UNION BANK, N.A. as a "New Revolving Loan Lender"
		
	By:  
	/s/ Michael Tschida     
Name: Michael Tschida 
Title:    Vice President

Notice Address: 
445 S Figueroa Street 
16th Floor 
Los Angeles, CA 90071
Attention: Michael Tschida 
Telephone: (213) 236-5273 
Facsimile: (213) 236-7636
HSBC BANK CANADA as a "New Revolving Loan Lender"
		
	By:  
	/s/ Andrew Sclater     
Name:    Andrew Sclater 
Title:    Global Relationship Manager, 
        Corporate Banking

[Signature Page to Joinder Agreement]

		
	By:  
	/s/ Ambar Bansal     
Name:    Ambar Bansal 
Title:    Vice President, 
        Regional Head of Corporate 
        HSBC Bank of Canada

EXPORT DEVELOPMENT CANADA as a "New Revolving Loan Lender"
		
	By:  
	/s/ Arturo Polisena     
Name:    Arturo Polisena 
Title:    Senior Associate

		
	By:  
	/s/ Janine Dopson     
Name:    Janine Dopson 
Title:    Financing Manager

Notice Address: 
Export Development Canada 
150 Slater Street 
Ottawa, Ontario; K1A 1K3
Attention: Arturo Polisena 
Telephone: (613) 598-3182 
Facsimile: (613) 598-3186
ROYAL BANK OF CANADA as a "New Revolving Loan Lender"
		
	By:  
	/s/ Dean Sas     
Name:    Dean Sas 
Title:    Authorized Signatory

[Signature Page to Joinder Agreement]

JPMORGAN CHASE BANK, N.A., TORONTO BRANCH as a "New Revolving Loan Lender"
		
	By:  
	/s/ Michael N. Tam     
Name:    Michael N. Tam 
Title:    Senior Vice President

THE TORONTO DOMINION BANK, as a "New Revolving Loan Lender"
		
	By:  
	/s/ Scott Rogers     
Name:    Scott Rogers 
Title:    Associate VP, TD Commercial 
        Bank

		
	By:  
	/s/ Nigel Sharpley     
Name:    Nigel Sharpley 
Title:    Senior Manager, TD Commercial 
        Bank

Notice Address: 
Canadian Pacific Tower 
100 Wellington Street West, 26th Floor 
Toronto, Ontario M5K 1A2
Attention: Nigel Sharpley 
Telephone: (416) 983-8686 
Facsimile: (416) 308-3733

[Signature Page to Joinder Agreement]

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. 
as Borrower
By:        /s/ Rajiv De Silva     
    Name:    Rajiv De Silva 
    Title:    President & Chief Operating Officer
VALEANT PHARMACEUTICALS INTERNATIONAL 
as Guarantor
By:        /s/ Rajiv De Silva     
    Name:    Rajiv De Silva 
    Title:    President & Chief Operating Officer
ATON PHARMA, INC. 
as Guarantor
By:        /s/ Rajiv De Silva     
    Name:    Rajiv De Silva 
    Title:    President & Chief Operating Officer
CORIA LABORATORIES, LTD. 
as Guarantor
By:        /s/ Rajiv De Silva     
    Name:    Rajiv De Silva 
    Title:    President & Chief Operating Officer
DOW PHARMACEUTICAL SCIENCES, INC. 
as Guarantor
By:        /s/ Rajiv De Silva     
    Name:    Rajiv De Silva 
    Title:    President & Chief Operating Officer

[Signature Page to Joinder Agreement]

VALEANT PHARMACEUTICALS NORTH AMERICA LLC 
as Guarantor
By:        /s/ Rajiv De Silva     
    Name:    Rajiv De Silva 
    Title:    President
DR. LEWINN'S PRIVATE FORMULA INTERNATIONAL, INC. 
as Guarantor
By:        /s/ Rajiv De Silva     
    Name:    Rajiv De Silva 
    Title:    President
OCEANSIDE PHARMACEUTICALS, INC. 
as Guarantor
By:        /s/ Rajiv De Silva     
    Name:    Rajiv De Silva 
    Title:    President
PRINCETON PHARMA HOLDINGS, LLC 
as Guarantor
By:        /s/ Rajiv De Silva     
    Name:    Rajiv De Silva 
    Title:    President
PRIVATE FORMULA CORP. 
as Guarantor
By:        /s/ Rajiv De Silva     
    Name:    Rajiv De Silva 
    Title:    President

[Signature Page to Joinder Agreement]

RENAUD SKIN CARE LABORATORIES, INC. 
as Guarantor
By:        /s/ Rajiv De Silva     
    Name:    Rajiv De Silva 
    Title:    President
VALEANT BIOMEDICALS, INC. 
as Guarantor
By:        /s/ Rajiv De Silva     
    Name:    Rajiv De Silva 
    Title:    President
BIOVAIL AMERICAS CORP. 
as Guarantor
By:        /s/ Rajiv De Silva     
    Name:    Rajiv De Silva 
    Title:    President
PRESTWICK PHARMACEUTICALS, INC. 
as Guarantor
By:        /s/ Rajiv De Silva     
    Name:    Rajiv De Silva 
    Title:    President
ORAPHARMA, INC. 
as Guarantor
By:        /s/ Steve Sembler     
    Name:     Steve Sembler 
    Title:    Chief Commercial Officer

[Signature Page to Joinder Agreement]

ORAPHARMA TOPCO HOLDINGS, INC. 
as Guarantor
By:        /s/ Howard B. Schiller     
    Name:    Howard B. Schiller 
    Title:    Executive Vice President, Chief      
        Financial Officer and Treasurer
VALEANT HOLDINGS (BARBADOS) SRL 
as Guarantor
By:        /s/ Mauricio Zavala     
    Name:    Mauricio Zavala 
    Title:    Manager
HYTHE PROPERTY INCORPORATED 
as Guarantor
By:        /s/ Alex Matheson     
    Name:    Alex Matheson 
    Title:    Senior Director
VALEANT PHARMACEUTICALS HOLDINGS (BARBADOS) SRL 
as Guarantor
By:        /s/ Mauricio Zavala     
    Name:    Mauricio Zavala 
    Title:    Assistant Secretary

[Signature Page to Joinder Agreement]

VALEANT INTERNATIONAL BERMUDA 
as Guarantor
By:        /s/ Peter McCurdy     
    Name:    Peter McCurdy 
    Title:    Director, President and Assistant      
        Secretary
VALEANT PHARMACEUTICALS HOLDINGS BERMUDA 
as Guarantor
By:        /s/ Peter McCurdy     
    Name:    Peter McCurdy 
    Title:    Director, President and Assistant      
        Secretary
VALEANT PHARMACEUTICALS NOMINEE BERMUDA 
as Guarantor
By:        /s/ Peter McCurdy     
    Name:    Peter McCurdy 
    Title:    Director, President and Assistant      
        Secretary
VALEANT CANADA GP LIMITED 
as Guarantor
By:        /s/ Robert R. Chai-Onn     
    Name:    Robert R. Chai-Onn 
    Title:    Vice President
VALEANT CANADA LP by its sole general partner, VALEANT CANADA GP LIMITED 
as Guarantor
By:        /s/ Robert R. Chai-Onn     
    Name:    Robert R. Chai-Onn 
    Title:    Director

[Signature Page to Joinder Agreement]

V-BAC HOLDING CORP. 
as Guarantor
By:        /s/ Robert R. Chai-Onn     
    Name:    Robert R. Chai-Onn 
    Title:    Vice President

VALEANT PHARMACEUTICALS IRELAND 
as Guarantor
By:        /s/ Graham Jackson     
    Name:    Graham Jackson 
    Title:    Director

BIOVAIL INTERNATIONAL S.À R.L. 
as Guarantor
By:        /s/ Kuy Ly Ang     
    Name:    Kuy Ly Ang 
    Title:    Director
VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L. 
as Guarantor
By:        /s/  Kuy Ly Ang     
    Name:    Kuy Ly Ang 
    Title:      Manager    
PHARMASWISS SA 
as Guarantor
By:        /s/ Matthias Courvoisier     
    Name:    Matthias Courvoisier 
    Title:    Chairman

[Signature Page to Joinder Agreement]

	
			
	Signed by
	 
	 

	Valeant Holdco 2 Pty Ltd (ACN 154 341 367)
	 
	 

	as Guarantor
	 
	 

	in accordance with section 127 of the Corporations Act 2001 by two directors:
	 
	 

	 
	 
	 

	 
	 
	 

	/s/ Robert Chai-Onn
	 
	/s/ Rajiv De Silva

	Signature of director
	 
	Signature of director

	 
	 
	 

	Robert Chai-Onn
	 
	Rajiv De Silva

	 
	 
	 

	Name of director (please print)
	 
	Name of director (please print)

	
			
	Signed by
	 
	 

	Wirra Holdings Pty Limited (ACN 122 216 577)
	 
	 

	as Guarantor
	 
	 

	in accordance with section 127 of the Corporations Act 2001 by two directors:
	 
	 

	 
	 
	 

	 
	 
	 

	/s/ Robert Chai-Onn
	 
	/s/ Howard B. Schiller

	Signature of director
	 
	Signature of director

	 
	 
	 

	Robert Chai-Onn
	 
	Howard B. Schiller

	 
	 
	 

	Name of director (please print)
	 
	Name of director (please print)

[Signature Page to Joinder Agreement]

	
			
	Signed by
	 
	 

	Wirra Operations Pty Limited (ACN 122 250 088)
	 
	 

	as Guarantor
	 
	 

	in accordance with section 127 of the Corporations Act 2001 by two directors:
	 
	 

	 
	 
	 

	 
	 
	 

	/s/ Robert Chai-Onn
	 
	/s/ Howard B. Schiller

	Signature of director
	 
	Signature of director

	 
	 
	 

	Robert Chai-Onn
	 
	Howard B. Schiller

	 
	 
	 

	Name of director (please print)
	 
	Name of director (please print)

	
			
	Signed by
	 
	 

	iNova Pharmaceuticals (Australia) Pty Limited (ACN 000 222 408)
	 
	 

	as Guarantor
	 
	 

	in accordance with section 127 of the Corporations Act 2001 by two directors:
	 
	 

	 
	 
	 

	 
	 
	 

	/s/ Robert Chai-Onn
	 
	/s/ Howard B. Schiller

	Signature of director
	 
	Signature of director

	 
	 
	 

	Robert Chai-Onn
	 
	Howard B. Schiller

	 
	 
	 

	Name of director (please print)
	 
	Name of director (please print)

[Signature Page to Joinder Agreement]

	
			
	Signed by
	 
	 

	iNova Sub Pty Limited (ACN 134 398 815)
	 
	 

	as Guarantor
	 
	 

	in accordance with section 127 of the Corporations Act 2001 by two directors:
	 
	 

	 
	 
	 

	 
	 
	 

	/s/ Robert Chai-Onn
	 
	/s/ Howard B. Schiller

	Signature of director
	 
	Signature of director

	 
	 
	 

	Robert Chai-Onn
	 
	Howard B. Schiller

	 
	 
	 

	Name of director (please print)
	 
	Name of director (please print)

	
			
	Signed by
	 
	 

	Wirra IP Pty Limited (ACN 122 536 350)
	 
	 

	as Guarantor
	 
	 

	in accordance with section 127 of the Corporations Act 2001 by two directors:
	 
	 

	 
	 
	 

	 
	 
	 

	/s/ Robert Chai-Onn
	 
	/s/ Howard B. Schiller

	Signature of director
	 
	Signature of director

	 
	 
	 

	Robert Chai-Onn
	 
	Howard B. Schiller

	 
	 
	 

	Name of director (please print)
	 
	Name of director (please print)

    

[Signature Page to Joinder Agreement]

Consented to by:
GOLDMAN SACHS LENDING PARTNERS LLC 
As Administrative Agent and Collateral Agent
By:      /s/ Elizabeth Fischer     
    Authorized Signatory
Name:    Elizabeth Fischer 
Title:    Authorized Signatory

[Signature Page to Joinder Agreement]

SCHEDULE A 
TO JOINDER AGREEMENT

	
			
	Name of Lender
	Type of Commitment
	Amount

	CITIBANK, N.A.
	New Revolving Loan Commitment
	$35,000,000

	DBS BANK LTD., LOS ANGELES AGENCY
	New Revolving Loan Commitment
	$20,000,000

	SUNTRUST BANK
	New Revolving Loan Commitment
	$18,587,500

	BANK OF AMERICA, N.A.
	New Revolving Loan Commitment
	$16,250,000

	GOLDMAN SACHS LENDING PARTNERS LLC
	New Revolving Loan Commitment
	$10,437,500

	MORGAN STANLEY BANK, N.A.
	New Revolving Loan Commitment
	$10,062,500

	BARCLAYS BANK PLC
	New Revolving Loan Commitment
	$10,000,000

	THE BANK OF NOVA SCOTIA
	New Revolving Loan Commitment
	$9,375,000

	DNB BANK ASA (F/K/A DNB NOR BANK ASA)
	New Revolving Loan Commitment
	$9,375,000

	UNION BANK, N.A.
	New Revolving Loan Commitment
	$6,562,500

	HSBC BANK CANADA
	New Revolving Loan Commitment
	$6,200,000

	EXPORT DEVELOPMENT CANADA
	New Revolving Loan Commitment
	$5,937,500

	ROYAL BANK OF CANADA
	New Revolving Loan Commitment
	$5,937,500

	J.P. MORGAN CHASE BANK, N.A., TORONTO BRANCH
	New Revolving Loan Commitment
	$5,900,000

	THE TORONTO-DOMINION BANK
	New Revolving Loan Commitment
	$5,375,000

	 
	 
	Total:  $175,000,000Exhibit 10.6

Exhibit 10.6
	
				
	JPMORGAN CHASE BANK, N.A. 
270 Park Avenue 
New York, New York  10017
J.P. MORGAN SECURITIES LLC 
383 Madison Avenue 
New York, New York  10017

	GOLDMAN SACHS LENDING PARTNERS LLC 
200 West Street 
New York, New York  10282
	ROYAL BANK OF CANADA
Three World Financial Center
200 Vesey Street

	MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED 
BANK OF AMERICA, N.A. 
One Bryant Park 
New York, NY 10036
	MORGAN STANLEY SENIOR FUNDING, INC.
1585 Broadway
New York, NY  10036

	BARCLAYS 
745 Seventh Avenue 
New York, NY 10019
	SUNTRUST ROBINSON HUMPHREY, INC.
SUNTRUST BANK
3333 Peachtree Road
Atlanta, Georgia 30326
	DNB BANK ASA
DNB MARKETS, INC.
200 Park Avenue
New York, NY 10166
	THE BANK OF NOVA SCOTIA
40 King Street West
Scotia Plaza
Toronto, Ontario
Canada
M5W 2X6

PERSONAL AND CONFIDENTIAL
September 11, 2012
Valeant Pharmaceuticals International, Inc. 
4787 Levy Street 
Montreal, Quebec 
Canada H4R 2P9
Valeant Pharmaceuticals International 
700 Route 202/206 
Bridgewater, NJ   08807
Attention:  J. Michael Pearson
Amended and Restated Commitment Letter
Ladies and Gentlemen:
We are pleased to confirm the arrangements under which each of JPMorgan Chase Bank, N.A. ("JPMCB"), J.P. Morgan Securities LLC ("J.P. Morgan"), Goldman Sachs Lending Partners LLC ("GSLP"), Royal Bank of Canada ("Royal Bank"), RBC Capital Markets ("RBCCM"), Bank of America, N.A. ("BOA"), Merrill Lynch, Pierce, Fenner & Smith Incorporated ("Merrill Lynch"), Morgan Stanley Senior Funding, Inc. ("Morgan Stanley"), Barclays Bank PLC ("Barclays"), SunTrust Bank ("SunTrust"), SunTrust Robinson Humphrey, Inc. ("STRH"), DNB Bank ASA ("DNB"), DNB Markets, Inc. ("DNB Markets") and The Bank of Nova Scotia ("BONS")  (collectively, the 

"Commitment Parties") is exclusively authorized by Valeant Pharmaceuticals International, Inc., a corporation organized under the laws of Canada (the "Parent"), and Valeant Pharmaceuticals International, a Delaware corporation (the "Company" and, together with Parent, "you"), to act, in the case of J.P. Morgan as joint lead arranger, joint bookrunner and sole syndication agent, in the case of GSLP and Royal Bank as joint bookrunners and in the case of GSLP, Royal Bank, Merrill Lynch, Morgan Stanley, Barclays, SunTrust, DNB Markets and BONS as co-documentation agents, each in connection with the financing for certain transactions described herein, in each case on the terms and subject to the conditions set forth in this amended and restated commitment letter and the attached Annexes A, B and C hereto (collectively, this "Commitment Letter").  Capitalized terms used but not defined herein have the respective meanings given in the Annexes hereto.  
You have informed the Commitment Parties that Parent intends to consummate the acquisition (the "Acquisition") of 100% of the capital stock of an entity previously identified to us and referred to as "Merlin" (the "Target," and together with its subsidiaries, the "Acquired Business") pursuant to the merger agreement, dated as of September 2, 2012, among Parent, the Company and one of the Company's other wholly owned domestic subsidiaries ("Acquisition Sub") and the Target (together with the schedules and exhibits thereto, the "Acquisition Agreement").  The Acquisition will be consummated pursuant to the Acquisition Agreement whereby Acquisition Sub will be merged with and into Target, with Target surviving the merger as a wholly owned subsidiary of Parent and the Company, in which case all of the outstanding Shares of Target on the date of consummation of the Acquisition (the "Closing Date") (other than Shares held by Parent, Acquisition Sub or any other direct or indirect wholly owned subsidiary of Parent and shares owned by the Company, in each case not held on behalf of third parties, and other than shares that are owned by stockholders who have perfected and not withdrawn a demand for appraisal rights) will be converted into the right to receive on the Closing Date the cash consideration per Share set forth in the Acquisition Agreement.  You have informed us that (a) the Acquisition, (b) the Target's obligation to pay the conversion consideration with respect to, or repurchase, as applicable, the Target's notes under, and in accordance with, the following indentures:  (i) 2.5% Contingent Convertible Senior Notes due 2032 in the principal amount of $168.9 million, (ii) 1.5% Contingent Convertible Senior Notes due 2033 in the principal amount of $0.2 million and (iii) 1.375% Convertible Senior Notes due 2017 in the principal amount of $422.2 million (collectively, the "Target Indentures") and (c) the Transaction Expenses will be financed from the following sources:  
		
	•
	the issuance by the Borrower (as defined in Annex B) of $2,750 million of high yield securities (the "Securities") pursuant to a Rule 144A (without registration rights) or other private placement (the "Notes Offering") or, in the event some or all of the Securities are unable to be issued at the time the Acquisition is consummated, borrowings by the Company of unsecured senior increasing rate bridge loans in an aggregate principal amount of $2,750 million less the gross proceeds from the sale of Securities issued on or prior to the Closing Date (the "Bridge Loans", the "Facility" and the "Bridge Facility") having the terms set forth on Annex B.

		
	1.
	Commitments:  Titles and Roles.

Each of J.P. Morgan, GSLP, Royal Bank, Merrill Lynch, Morgan Stanley, Barclays, STRH, DNB Markets and BONS (collectively, the "Bridge Lead Arrangers" or, the "Arrangers") is pleased to confirm its commitment to act, and you hereby appoint J.P. Morgan to act as joint lead arranger, joint bookrunner and sole syndication agent (the "Syndication Agent"), GSLP and Royal Bank as joint bookrunners, GSLP, Royal Bank, Merrill Lynch, Morgan Stanley, Barclays, SunTrust, DNB Markets and BONS as co-documentation agents (the "Co-Documentation Agents") and each of JPMCB, GSLP, Royal Bank, BOA, 

2

Morgan Stanley, Barclays, SunTrust, DNB and BON is pleased to advise you of its several, but not joint, commitment to provide the percentage of the aggregate principal amount of the Bridge Loans set forth on each of their respective signature pages attached hereto (which sum to 100%), in each case on the terms and subject to the conditions contained in this Commitment Letter and the Fee Letter (referred to below).  In addition, you hereby appoint JPMCB to act as administrative agent (the "Bridge Administrative Agent") for the Bridge Facility.  You agree that J.P. Morgan will have "left" placement in any and all marketing materials or other documentation used in connection with the Facility or other documentation used in connection with the Facility.  You further agree that no other titles will be awarded and no compensation (other than that expressly contemplated by this Commitment Letter and the Fee Letter referred to below) will be paid in connection with the Facility unless you and we shall so agree.  Our fees for our commitment and for services related to the Facility are set forth in a separate amended and restated fee letter (the "Fee Letter") entered into by the Company and the Commitment Parties on the date hereof, which amends, restates and supersedes in its entirety the fee letter dated September 2, 2012 (the "Original Fee Letter") among JPMCB, J.P. Morgan, the Parent and the Company.
		
	2.
	Conditions Precedent.

Each Commitment Party's commitment and agreements hereunder are subject to the following condition:  since December 31, 2011, there has not occurred any circumstance, occurrence or development which, individually or in the aggregate, has had or is reasonably likely to have a Material Adverse Effect (as defined below).  Each Commitment Party's commitment and agreements hereunder are subject to the satisfactory negotiation, execution and delivery of appropriate definitive loan documents relating to the Facility including, without limitation, credit agreements, guarantees, opinions of counsel and other related definitive documents (collectively, the "Facility Documentation") to be based upon and substantially consistent with the terms set forth in this Commitment Letter (it being agreed that the Facility Documentation shall not contain any conditions precedent to the initial borrowing under the Facility on the Closing Date other than the conditions precedent expressly set forth herein, in Annex B under the heading "Conditions Precedent to Borrowing" and in Annex C hereto, and the terms of the Facility Documentation will be such that they do not impair the availability of the Facility on the Closing Date if such conditions are satisfied).  Each Commitment Party's commitment is also subject to the Company having entered into an engagement letter with one or more investment banks (the "Investment Banks") reasonably acceptable to the Commitment Parties, pursuant to which you engaged the Investment Banks in connection with a potential issuance of Securities).  Notwithstanding anything in this Commitment Letter, the Fee Letter or the Facility Documentation to the contrary, the only representations the accuracy of which will be a condition to the availability of the Bridge Loans on the Closing Date will be (i)  the representations and warranties made by the Acquired Business in the Acquisition Agreement that are material to the interests of the Lenders, in their capacities as such, but only to the extent that you have the right to terminate your obligations under the Acquisition Agreement or to decline to consummate the Acquisition (in each case in accordance with the terms of the Acquisition Agreement) as a result of a breach of such representation or warranty and (ii) the Specified Representations (as defined below).
As used herein, "Specified Representations" means representations relating to incorporation or formation; organizational power and authority to enter into the documentation relating to the Bridge Loans; due execution, delivery and enforceability of such documentation; solvency; no conflicts with charter documents; Federal Reserve margin regulations; the Investment Company Act, Patriot Act; and status of the Bridge Loans as senior debt and "Specified Acquisition Agreement Representations" shall mean the representations and warranties made by the Acquired Business in the Acquisition Agreement that are material to the interests of the Lenders, in their capacities as such, but only to the extent that you have the right to terminate your obligations under the Acquisition Agreement or to decline to consummate 

3

the Acquisition (in each case in accordance with the terms of the Acquisition Agreement) as a result of a breach of such representation or warranty.
As used in this Section 2, "Material Adverse Effect" means any material adverse effect on the financial condition, properties, assets, liabilities, business or results of operations of the Target and its Subsidiaries, taken as a whole; provided, however, that none of the following, in and of itself or themselves, shall constitute a Material Adverse Effect: (A) changes in the economy or financial markets generally in the United States or any foreign jurisdiction; (B) changes that are the result of factors generally affecting the pharmaceutical industry; (C) changes in United States generally accepted accounting principles; (D) any geopolitical conditions, the outbreak or escalation of hostilities, any acts of war, sabotage, terrorism or military actions, or any escalation or worsening of any such hostilities, acts of war, sabotage, terrorism or military actions threatened or underway as of September 2, 2012; (E) any general regulatory, legislative or political conditions or securities, credit, financial or other capital market conditions, in each case in the United States or any foreign jurisdiction; (F) changes in Law, including rules, regulations and administrative policies of the U.S. Food and Drug Administration or interpretations thereof, in each case of general applicability; (G) any legal proceedings made or brought by any of the current or former securityholders of the Target (on their own behalf or on behalf of the Target) arising out of or related to the Acquisition Agreement or any of the transactions contemplated thereby; (H) earthquakes, hurricanes, tornados or other natural disasters; (I) a decline in the price of Target's shares on the New York Stock Exchange, provided that the exception in this clause shall not prevent or otherwise affect a determination that any change, effect, circumstance or development underlying such decline has resulted in, or contributed to, a Material Adverse Effect; (J) the announcement or pendency of the Acquisition Agreement or the transactions contemplated thereby, including the effect on employees, customers, suppliers, distributors and collaboration partners; (K) any failure by the Target to meet any estimates of revenues or earnings or other financial or operating metrics (whether such projections were made by the Target or independent third parties) for any period ending on or after September 2, 2012 and prior to the Closing Date, provided that the exception in this clause shall not prevent or otherwise affect a determination that any change, effect, circumstance or development underlying such failure has resulted in, or contributed to, a  Material Adverse Effect; (L) the approval or disapproval by, or the delay of a determination of approval or disapproval by the U.S. Food and Drug Administration or any Governmental Entity or any panel or advisory body empowered or appointed thereby, with respect to the Company Products; and (M) any action expressly required to be taken or not taken with the consent of the Company (which consent is made with the consent of the Arrangers not to be unreasonably withheld or delayed) or pursuant to or in accordance with the Acquisition Agreement; provided, further, that, with respect to clauses (A), (B), (C), (D), (E) and (F), such change, event, circumstance or development does not (i) primarily relate only to (or have the effect of primarily relating to) the Target and its Subsidiaries or (ii) have a disproportionate adverse effect on the Target and its Subsidiaries compared to other companies of similar size operating in the pharmaceutical industry.  Capitalized terms used in the preceding definition that are not otherwise defined in this Commitment Letter shall have the meanings given to them in the Acquisition Agreement as in effect on September 2, 2012.
		
	3.
	Syndication.

The Arrangers intend, and reserve the right, to syndicate the Facility to the Lenders promptly following the date hereof, and you acknowledge and agree that the commencement of syndication shall occur in the discretion of the Arrangers.  The Arrangers will select the Lenders after consultation with you.  The Arrangers will lead the syndication, including determining the timing of all offers to potential Lenders, any title of agent or similar designations or roles awarded to any Lender and the acceptance of commitments, the amounts offered and the compensation provided to each Lender from the amounts to be 

4

paid to the Arrangers pursuant to the terms of this Commitment Letter and the Fee Letter.  The Arrangers will, in consultation with you, determine the final commitment allocations and will notify the Company of such determinations.  You agree to use commercially reasonable efforts to ensure that the Arrangers' syndication efforts benefit from the existing lending relationships of Parent, the Company and Target and their respective subsidiaries.  To facilitate an orderly and successful syndication of the Facility, you agree that, until the earliest of (x) the termination of the syndication as determined by the Arrangers, (y) the consummation of a Successful Syndication (as defined in the Fee Letter) and (z) 90 days after the Closing Date, neither the Company, Parent nor Target (including, in each case, their respective subsidiaries) will syndicate or issue, attempt to syndicate or issue, announce or authorize the announcement of the syndication or issuance of, any debt facility or any debt or equity security of the Parent or the Company or any of their respective subsidiaries or affiliates other than (a) the Facility and other indebtedness contemplated hereby to remain outstanding after the Closing Date, (b) the issuance of the Securities (if any), (c) equity issued in connection with the conversion or settlement of any convertible debt securities or in connection with any hedging arrangements or warrants of the Company, Parent, Target or their respective subsidiaries, (d) equity issued pursuant to employee stock plans of the Company, Parent, Target or their respective subsidiaries and other similar arrangements to be mutually agreed upon by you and the Arrangers and (e) the $175 million incremental revolving facility under the Third Amended and Restated Credit and Guaranty Agreement, dated as of February 13, 2012 (as amended, amended and restated or supplemented from time to time, the "Credit Agreement"), by and among Parent, certain subsidiaries of Parent as guarantors, the various lenders, issuing banks and agents party thereto and Goldman Sachs Lending Partners LLC, as administrative agent and collateral agent (in such capacity, the "Administrative Agent")) without the prior written consent of the Arrangers.
You agree to cooperate with the Commitment Parties, in connection with (i) the preparation of one or more information packages regarding the business, operations and financial projections of Parent, the Company and the Acquired Business (collectively, the "Confidential Information Memorandum") including, without limitation, all information relating to the transactions contemplated hereunder prepared by or on behalf of the Company deemed reasonably necessary by the Arrangers to complete the syndication of the Facility including, without limitation, using commercially reasonable efforts to obtain, prior to the launch of syndication, (a) a public corporate family rating from Moody's Investors Service, Inc. ("Moody's") for the Company, (b) a public corporate credit rating from Standard & Poor's Ratings Group, a division of The McGraw Hill Corporation ("S&P") for the Company and (c) a public credit rating for the Facility and any Securities issued in lieu thereof from each of Moody's and S&P, and (ii) the presentation of one or more information packages reasonably acceptable in format and content to the Commitment Parties (collectively, the "Lender Presentation") in meetings and other communications with prospective Lenders or agents in connection with the syndication of the Facility (including, without limitation, direct contact between senior management and representatives, with appropriate seniority and expertise, of Parent and the Company with prospective Lenders and participation of such persons in meetings upon reasonable advance notice and at mutually agreed times).  You will be solely responsible for the contents of any such Confidential Information Memorandum and Lender Presentation (other than, in each case, any information contained therein that has been provided for inclusion therein by the Commitment Parties solely to the extent such information relates to the Commitment Parties) and all other information, documentation or materials delivered to the Arrangers in connection therewith (collectively, the "Information") and you acknowledge that the Commitment Parties will be using and relying upon the Information without independent verification thereof.  You agree that Information regarding the Facility and Information provided by the Company and Target or their respective representatives to the Arrangers in connection with the Facility (including, without limitation, draft and execution versions of the Facility Documentation, the Confidential Information Memorandum, the Lender Presentation, publicly filed financial statements, and draft or final offering materials relating to 

5

contemporaneous securities issuances by the Company or Parent) may be disseminated to potential Lenders and other persons through one or more internet sites (including an IntraLinks, SyndTrak or other electronic workspace (the "Platform")) created for purposes of syndicating the Facility or otherwise, in accordance with the Arrangers' standard syndication practices, and you acknowledge that neither the Arrangers nor any of its affiliates will be responsible or liable to you or any other person or entity for damages arising from the use by others of any Information or other materials obtained on the Platform, except, in the case of damages to you but not to any other person, to the extent such damages are found by a final judgment of a court of competent jurisdiction to arise from the gross negligence or willful misconduct of any Arranger or any of their affiliates or any of their respective directors, employees, advisors or agents.
You acknowledge that certain of the Lenders may be "public side" Lenders (i.e. Lenders that do not wish to receive material non-public information with respect to the Company, Parent, Target or their respective affiliates or any of its or their respective securities) (each, a "Public Lender").  At the request of the Arrangers, you agree to prepare an additional version of the Confidential Information Memorandum and the Lender Presentation to be used by Public Lenders that does not contain material non-public information concerning the Company, Parent, the Target or their respective affiliates or securities.  It is understood that in connection with your assistance described above, at the request of the Arrangers, you will provide, and cause all other applicable persons to provide (including use reasonable efforts to cause the Target to provide) authorization letters to the Arrangers authorizing the distribution of the Information to prospective Lenders, containing a representation to the Arrangers that the public-side version does not include material non-public information about the Company, Parent, the Target or their respective affiliates or its or their respective securities.  In addition, you will clearly designate as such all Information provided to the Commitment Parties by or on behalf of the Company or the Target which is suitable to make available to Public Lenders.  You acknowledge and agree that the following documents may be distributed to Public Lenders, unless you advise the Arrangers in writing (including by email) within a reasonable time prior to their intended distributions that such material should only be distributed to prospective Lenders that are not Public Lenders:  (a) drafts and final versions of the Facility Documentation; (b) administrative materials prepared by the Arrangers for prospective Lenders (such as a lender meeting invitation, allocations and funding and closing memoranda); and (c) term sheets and notification of changes in the terms of the Facility.
		
	4.
	Information.

You represent and covenant that (i) to the best of your knowledge in the case of Information relating to the Acquired Business, all written Information (other than financial projections and information of a general economic or industry specific nature) provided directly or indirectly by the Company to the Commitment Parties or the Lenders in connection with the transactions contemplated hereunder is and will be, when furnished and when taken as a whole and giving effect to all supplements thereto, complete and correct in all material respects and does not and will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements contained therein, in light of the circumstances under which they were made, not materially misleading and (ii) the financial projections that have been or will be made available to the Commitment Parties or the Lenders in connection with the transactions contemplated hereunder by or on behalf of the Company have been and will be prepared in good faith based upon assumptions that are believed by the preparer thereof to be reasonable at the time such financial projections are furnished to the Commitment Parties or the Lenders, it being understood and agreed that financial projections are not a guarantee of financial performance and actual results may differ from financial projections and such differences may be material.  You agree that if at any time prior to the Successful Syndication of the Facility, any of the representations in the preceding sentence would 

6

be incorrect in any material respect if the Information and financial projections were being furnished, and such representations were being made, at such time, then you will promptly supplement, or cause to be supplemented, the Information and financial projections so that such representations will be correct in all material respects under those circumstances.
		
	5.
	Indemnification and Related Matters.

In connection with arrangements such as this, it is the Commitment Parties' policy to receive indemnification.  You agree to the provisions with respect to our indemnity and other matters set forth in Annex A, which is incorporated by reference into this Commitment Letter.
		
	6.
	Assignments; Amendments.

This Commitment Letter may not be assigned by you without the prior written consent of the Commitment Parties (and any purported assignment without such consent will be null and void), is intended to be solely for the benefit of the Commitment Parties and the other parties hereto and, except as set forth in Annex A hereto, is not intended to confer any benefits upon, or create any rights in favor of, any person other than the parties hereto.  Each of the Commitment Parties, after consultation with you, may assign its commitments and agreements hereunder, in whole or in part, to any of its affiliates (provided that such affiliates agree to abide by the confidentiality provisions of Section 7 of this Commitment Letter) and, as provided above, to any Lender prior to the Closing Date; provided that any assignment by a Commitment Party to any potential Lender made prior to the Closing Date shall not relieve such Commitment Party of its obligations set forth herein to fund that portion of the commitments so assigned.  Neither this Commitment Letter nor the Fee Letter may be amended or any term or provision hereof or thereof waived or otherwise modified except by an instrument in writing signed by each of the parties hereto or thereto, as applicable, and any term or provision hereof or thereof may be amended or waived only by a written agreement executed and delivered by all parties hereto or thereto.
		
	7.
	Confidentiality.

Please note that this Commitment Letter, the Fee Letter and any written communications provided by, or oral discussions with, the Commitment Parties in connection with this arrangement are exclusively for the information of the Company and may not be disclosed to any third party or circulated or referred to publicly without our prior written consent except, after providing written notice to the Commitment Parties, pursuant to a subpoena or order issued by a court of competent jurisdiction or by a judicial, administrative or legislative body or committee; provided that we hereby consent to your disclosure of (i) this Commitment Letter, the Fee Letter and such communications and discussions to the Parent's, the Company's and (on a redacted basis reasonably satisfactory to the Arrangers with respect to the Fee Letter) the Target's respective directors, employees, agents, accountants, legal counsel and other advisors who are directly involved in the consideration of the Facility and who have been informed by you of the confidential nature of such advice and the Commitment Letter and Fee Letter and who have agreed to treat such information confidentially, (ii) this Commitment Letter, the Fee Letter and such communications and discussions as required by applicable law, rule or regulation or compulsory legal process (in which case you agree to inform us promptly thereof to the extent not prohibited by law) and (iii) the information contained in Annex B to Moody's and S&P; provided that such information is supplied only on a confidential basis after consultation with the Commitment Parties.
Each Commitment Party agrees that it will treat as confidential all information provided to it hereunder by or on behalf of you or any of your respective subsidiaries or affiliates; provided that nothing herein will prevent any Commitment Party from disclosing any such information (a) pursuant to the order of any 

7

court or administrative agency or in any pending legal or administrative proceeding, or otherwise as required by applicable law or compulsory legal process (in which case such person agrees (except with respect to any routine or ordinary course audit or examination conducted by bank accountants or any governmental bank regulatory authority exercising examination or regulatory authority) to inform you promptly thereof to the extent not prohibited by law), (b) upon the request or demand of any regulatory authority having jurisdiction over such person or any of its affiliates, (c) to the extent that such information is publicly available or becomes publicly available other than by reason of improper disclosure by such person, (d) to such person's affiliates and their respective officers, directors, partners, employees, legal counsel, independent auditors and other experts or agents who need to know such information and on a confidential basis, (e) to potential and prospective Lenders, participants and any direct or indirect contractual counterparties to any swap or derivative transaction relating to the Borrower and its obligations under the Facility, in each case, who are advised of the confidential nature of such information, (f) to Moody's and S&P; provided that such information is limited to Annexes B and C and is supplied only on a confidential basis after consultation with you or (g) for purposes of establishing a "due diligence" defense.  Each Commitment Party's obligation under this provision shall remain in effect until the earlier of (i) two years from September 2, 2012 and (ii) the date the definitive Facility Documentation is entered into by the Commitment Parties, at which time any confidentiality undertaking in the definitive Facility Documentation shall supersede this provision.  
		
	8.
	Absence of Fiduciary Relationship; Affiliates; Etc.

As you know, each Commitment Party, together with its respective affiliates (each collectively, a "Commitment Party Group"), is a full service financial services firm engaged, either directly or through affiliates, in various activities, including securities trading, investment banking and financial advisory, investment management, principal investment, hedging, financing and brokerage activities and financial planning and benefits counseling for both companies and individuals.  In the ordinary course of these activities, each Commitment Party Group may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and/or financial instruments (including bank loans) for their own account and for the accounts of their customers and may at any time hold long and short positions in such securities and/or instruments.  Such investment and other activities may involve securities and instruments of you or the Target, as well as of other entities and persons and their affiliates which may (i) be involved in transactions arising from or relating to the engagement contemplated by this Commitment Letter, (ii) be customers or competitors of you or the Target, or (iii) have other relationships with you or the Target.  In addition, each Commitment Party Group may provide investment banking, underwriting and financial advisory services to such other entities and persons.  Each Commitment Party Group may also co-invest with, make direct investments in, and invest or co-invest client monies in or with funds or other investment vehicles managed by other parties, and such funds or other investment vehicles may trade or make investments in your securities or those of such other entities.  The transactions contemplated by this Commitment Letter may have a direct or indirect impact on the investments, securities or instruments referred to in this paragraph.  Although each Commitment Party Group in the course of such other activities and relationships may acquire information about the transaction contemplated by this Commitment Letter or other entities and persons which may be the subject of the transactions contemplated by this Commitment Letter, no Commitment Party Group shall have any obligation to disclose such information, or the fact that such Commitment Party Group is in possession of such information, to you or to use such information on the Company's behalf.
Consistent with their respective policies to hold in confidence the affairs of its customers, no Commitment Party Group will furnish confidential information obtained from you by virtue of the transactions contemplated by this Commitment Letter to any other companies, or use such information in 

8

connection with the performance by such Commitment Party Group of services for any other companies.  Furthermore, you acknowledge that no Commitment Party Group and none of their respective affiliates has an obligation to use in connection with the transactions contemplated by this Commitment Letter, or to furnish to you, confidential information obtained or that may be obtained by them from any other person.
Each Commitment Party Group may have economic interests that conflict with yours, or those of your equity holders and/or affiliates.  You agree that each Commitment Party Group will act under this Commitment Letter as an independent contractor and that nothing in this Commitment Letter or the Fee Letter or otherwise will be deemed to create an advisory, fiduciary or agency relationship or fiduciary or other implied duty between any Commitment Party Group and you or your equity holders or affiliates.  You acknowledge and agree that the transactions contemplated by this Commitment Letter and the Fee Letter (including the exercise of rights and remedies hereunder and thereunder) are arm's-length commercial transactions between the Commitment Party Groups, on the one hand, and you on the other, and in connection therewith and with the process leading thereto, (i) no Commitment Party Group has assumed (A) an advisory or fiduciary responsibility in favor of you or your equity holders or affiliates with respect to the financing transactions contemplated hereby, or in each case, the exercise of rights or remedies with respect thereto or the process leading thereto (irrespective of whether such Commitment Party has advised, is currently advising or will advise you, your equity holders or your affiliates on other matters) or any other obligation to you except the obligations expressly set forth in this Commitment Letter and the Fee Letter and (ii) each Commitment Party Group is acting solely as a principal and not as the agent or fiduciary of you, your management, equity holders, affiliates, creditors or any other person.  You acknowledge and agree that you have consulted your own legal and financial advisors to the extent you deemed appropriate and that you are responsible for making your own independent judgment with respect to such transactions and the process leading thereto.  You agree that you will not claim that any Commitment Party Group has rendered advisory services of any nature or respect, or owes you a fiduciary or similar duty, in connection with such transactions or the process leading thereto.  
In addition, each Commitment Party may employ the services of its affiliates in providing services and/or performing their obligations hereunder and may exchange with such affiliates information concerning you and other companies that may be the subject of this arrangement, and such affiliates will be entitled to the benefits afforded to the Commitment Parties hereunder.
In addition, please note that the Commitment Parties do not provide accounting, tax or legal advice.  Notwithstanding anything herein to the contrary, you (and each of your employees, representatives and other agents) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the Facility and all materials of any kind (including opinions or other tax analyses) that are provided to you relating to such tax treatment and tax structure.  However, any information relating to the tax treatment or tax structure will remain subject to the confidentiality provisions hereof (and the foregoing sentence will not apply) to the extent reasonably necessary to enable the parties hereto, their respective affiliates, and their respective affiliates' directors and employees to comply with applicable securities laws.  For this purpose, "tax treatment" means U.S. federal or state income tax treatment, and "tax structure" is limited to any facts relevant to the U.S. federal income tax treatment of the transactions contemplated by this Commitment Letter but does not include information relating to the identity of the parties hereto or any of their respective affiliates.
		
	9.
	Miscellaneous.

9

Each Commitment Party's commitments and agreements hereunder will terminate upon the first to occur of (i) the consummation of the Acquisition, (ii) the abandonment or termination of the Acquisition Agreement, and (iii) March 4, 2013, subject to one extension to June 3, 2013 to the extent that the Termination Date (as defined in the Acquisition Agreement on the date of this Commitment Letter) is extended to June 3, 2013 in accordance with the terms of the Acquisition Agreement as in effect on the date of this Commitment Letter, unless the closing of (A) the Notes Offering or (B) the Bridge Loans under the Bridge Facility, as applicable, on the terms and subject to the conditions contained herein, has been consummated on or before such date.  Subject to the provisions of the next paragraph and the terms of the Fee Letter, you may terminate this Commitment Letter and/or each Commitment Party's commitments hereunder.  In addition, each Commitment Party's commitments hereunder to provide and arrange the Bridge Loans will be reduced to the extent of any issuance of the Securities (in escrow or otherwise).
The provisions set forth under Sections 3, 4, 5 (including Annex A) and 7 hereof and this Section 9 hereof will remain in full force and effect regardless of whether the definitive Facility Documentation is executed and delivered.  The provisions set forth under Sections 5 (including Annex A) and 7 hereof, this Section 9 and the fee and expense reimbursement provisions of the Fee Letter will remain in full force and effect notwithstanding the expiration or termination of this Commitment Letter or the Commitment Parties' commitments and agreements hereunder; provided that such provisions relating to indemnification and reimbursement shall terminate and be superseded by the terms of the Facility Documentation (to the extent such Facility Documentation becomes effective).
Each party hereto agrees for itself and its affiliates that any suit or proceeding arising in respect to this Commitment Letter or the Commitment Parties' commitments or agreements hereunder or the Fee Letter will be tried exclusively in the U.S. District Court for the Southern District of New York or, if that court does not have subject matter jurisdiction, in any state or federal court located in the Borough of Manhattan in the City of New York, and each party hereto agrees to submit to the exclusive jurisdiction of, and to venue in, such court.  Any right to trial by jury with respect to any action or proceeding arising in connection with or as a result of either the Commitment Parties' commitments or agreements or any matter referred to in this Commitment Letter or the Fee Letter is hereby waived by the parties hereto.  This Commitment Letter and the Fee Letter will be governed by and construed in accordance with the laws of the State of New York without regard to principles of conflicts of laws; provided that matters related to (x) any alleged Material Adverse Effect or exception thereto and (y) the determination of the accuracy of any Specified Acquisition Agreement Representation and whether, as a result of any inaccuracy thereof, you have the right to terminate or abandon your obligations under the Acquisition Agreement shall, in each case, be interpreted, construed and governed by and in accordance with the law of the State of Delaware without regard to the conflicts of law principles thereof to the extent that such principles would direct a matter to another jurisdiction.  
The Commitment Parties hereby notify you that pursuant to the requirements of the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the "Patriot Act") the Commitment Parties and each Lender may be required to obtain, verify and record information that identifies the Borrower and each of the Guarantors, which information includes the name and address of the Borrower and each of the Guarantors and other information that will allow the Commitment Parties and each Lender to identify the Borrower and each of the Guarantors in accordance with the Patriot Act.  This notice is given in accordance with the requirements of the Patriot Act and is effective for the Commitment Parties and each Lender.

10

This Commitment Letter may be executed in any number of counterparts, each of which when executed will be an original, and all of which, when taken together, will constitute one agreement.  Delivery of an executed counterpart of a signature page of this Commitment Letter by facsimile transmission or electronic transmission (in pdf or tif format) will be effective as delivery of a manually executed counterpart hereof.  This Commitment Letter and the Fee Letter are the only agreements that have been entered into among the parties hereto with respect to the Facility and set forth the entire understanding of the parties with respect thereto and supersede any prior written or oral agreements among the parties hereto with respect to the Facility.  This Commitment Letter amends, restates and supersedes in its entirety as of the date first above written the commitment letter dated September 2, 2012 (the "Original Commitment Letter") among JPMCB, J.P. Morgan, the Parent and the Company, and such Original Commitment Letter shall be of no further force and effect.  It is understood and agreed that JPMCB and J.P. Morgan shall be entitled to the benefits of the indemnification provisions of this Commitment Letter as if they were in effect on the date of the Original Commitment Letter.
[Remainder of page intentionally left blank]

11

Please confirm that the foregoing is in accordance with your understanding by signing and returning to the Commitment Parties the enclosed copy of this Commitment Letter, together, if not previously executed and delivered, with the Fee Letter on or before the close of business on September 11, 2012, whereupon this Commitment Letter and the Fee Letter will become binding agreements between us.  If the Commitment Letter and Fee Letter have not been signed and returned as described in the preceding sentence by such date, this offer will terminate on such date.  We look forward to working with you on this transaction.
Very truly yours,
JPMORGAN CHASE BANK, N.A.
By:        /s/ Anna C. Araya     
    Name:    Anna C. Araya 
    Title:    Vice President 
    Commitment Percentage: See Attached
J.P. MORGAN SECURITIES LLC
By:        /s/ John Stucker     
    Name:    John Stucker 
    Title:    Executive Director
GOLDMAN SACHS LENDING PARTNERS LLC
By:        /s/ Robert Ehudin     
    Name:    Robert Ehudin 
    Title:    Authorized Signatory 
    Commitment Percentage: See Attached
ROYAL BANK OF CANADA
By:        /s/ James S. Wolfe     
    Name:    James S. Wolfe 
    Title:    Managing Director 
        Head of US Leveraged Finance 
    Commitment Percentage: See Attached 

[Signature Page to Commitment Letter]

BANK OF AMERICA, N.A.
By:        /s/ Edward Martin     
    Name:    Edward Martin 
    Title:    Director 
    Commitment Percentage: See Attached
MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED
By:        /s/ Edward Martin     
    Name:    Edward Martin 
    Title:    Director
MORGAN STANLEY SENIOR FUNDING, INC. 
By:        /s/ Christy Silvester     
    Name:    Christy Silvester 
    Title:    Authorized Signatory 
    Commitment Percentage: See Attached 
BARCLAYS BANK PLC
By:        /s/ Jeremy Hazan     
    Name:    Jeremy Hazan 
    Title:    Director 
    Commitment Percentage: See Attached 
SUNTRUST BANK
By:        /s/ J. Ben Cumming     
    Name:  J. Ben Cumming 
    Title:    Director 
    Commitment Percentage: See Attached
SUNTRUST ROBINSON HUMPHREY, INC.
By:        /s/ Subhadra Shrivastava     
    Name:    Subhadra Shrivastava 
    Title:    Director

[Signature Page to Commitment Letter]

DNB Bank ASA
By:        /s/ Thomas Tangen     
    Name:    Thomas Tangen 
    Title:    SVP 
    Commitment Percentage: See Attached
DNB Bank ASA
By:        /s/ Bjorn Erik Hammerstad     
    Name:    Bjorn Erik Hammerstad 
    Title:    SVP 
    Commitment Percentage: See Attached
DNB Markets, Inc.
By:        /s/ Daniel M. Hochstadt     
    Name:    Daniel M. Hochstadt 
    Title:    Managing Director
DNB Markets, Inc.
By:        /s/ Tor Ivar Hansen     
    Name:    Tor Ivar Hansen 
    Title:    Managing Director
THE BANK OF NOVA SCOTIA
By:        /s/ James Rhee     
    Name:    James Rhee 
    Title:    Managing Director
THE BANK OF NOVA SCOTIA
By:        /s/ Christina Brennan     
    Name:    Christina Brennan 
    Title:    Managing Director 
    Commitment Percentage: See Attached

[Signature Page to Commitment Letter]

ACCEPTED AND AGREED AS OF THE DATE FIRST WRITTEN ABOVE:
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
By:        /s/ Howard B. Schiller     
    Name:    Howard B. Schiller 
    Title:    Executive Vice President and Chief Financial Officer
VALEANT PHARMACEUTICALS INTERNATIONAL
By:        /s/ Howard B. Schiller     
    Name:    Howard B. Schiller 
    Title:    Executive Vice President and Chief Financial Officer

[Signature Page to Commitment Letter]

Annex A
In the event that any Commitment Party becomes involved in any capacity in any action, proceeding or investigation brought by or against any person, including shareholders, partners, members or other equity holders of Parent, the Company or the Target in connection with or as a result of either this arrangement or any matter referred to in this Commitment Letter or the Fee Letter (together, the "Letters"), Parent and the Company, jointly and severally, agree to periodically reimburse each Commitment Party for its reasonable legal and other expenses (including the cost of any investigation and preparation) incurred in connection therewith.  Parent and the Company also agree to indemnify and hold each Commitment Party harmless against any and all losses, claims, damages or liabilities to any such person in connection with or as a result of either this arrangement or any matter referred to in the Letters (whether or not such investigation, litigation, claim or proceeding is brought by you, your equity holders or creditors or an indemnified person and whether or not any such indemnified person is otherwise a party thereto), except to the extent that such loss, claim, damage or liability (x) has been found by a final, non-appealable judgment of a court of competent jurisdiction to have resulted from (i) the gross negligence or willful misconduct of such Commitment Party in performing the services that are the subject of the Letters or (ii) a material breach of the obligations of such Commitment Party under the Letters or (y) has resulted from any dispute solely among the Commitment Parties.  If for any reason the foregoing indemnification is unavailable to any Commitment Party or insufficient to hold it harmless, then Parent and the Company will contribute to the amount paid or payable by the Commitment Party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative economic interests of (i) Parent, the Company and their respective affiliates, shareholders, partners, members or other equity holders on the one hand and (ii) the Commitment Parties on the other hand in the matters contemplated by the Letters as well as the relative fault of (i) Parent, the Company and their respective affiliates, shareholders, partners, members or other equity holders and (ii) the Commitment Parties with respect to such loss, claim, damage or liability and any other relevant equitable considerations.  The reimbursement, indemnity and contribution obligations of Parent and the Company under this paragraph will be in addition to any liability which Parent and the Company may otherwise have, will extend upon the same terms and conditions to any affiliate of a Commitment Party and the partners, members, directors, agents, employees and controlling persons (if any), as the case may be, of such Commitment Party and any such affiliate, and will be binding upon and inure to the benefit of any successors, assigns, heirs and personal representatives of Parent, the Company, each Commitment Party, any such affiliate and any such person.  Each of Parent and the Company also agrees that neither any indemnified party nor any of such affiliates, partners, members, directors, agents, employees or controlling persons will have any liability based on its or their exclusive or contributory negligence or otherwise to Parent, the Company or any person asserting claims on behalf of or in right of Parent, the Company or any other person in connection with or as a result of either this arrangement or any matter referred to in the Letters, except to the extent that any losses, claims, damages, liabilities or expenses incurred by Parent, the Company or their respective affiliates, shareholders, partners or other equity holders have been found by a final, non-appealable judgment of a court of competent jurisdiction to have resulted from the gross negligence or willful misconduct of such indemnified party in performing the services that are the subject of the Letters; provided, however, that in no event will such indemnified party or such other parties have any liability for any indirect, consequential, special or punitive damages in connection with or as a result of such indemnified party's or such other parties' activities related to the Letters.
Neither Parent nor the Company will be required to indemnify any Commitment Parties for any amount paid or payable by such Commitment Party in the settlement of any action, proceeding or investigation without such party's consent, which consent will not be unreasonably withheld or delayed; provided that the foregoing indemnity will apply to any such settlement in the event that Parent and/or the Company, as applicable, was

Annex A-1

 offered the ability to assume the defense of the action that was the subject matter of such settlement and elected not to so assume.  The provisions of this Annex A will survive any termination or completion of the arrangement provided by the Letters.

Annex A-2

Annex B
Summary of the Bridge Facility
This Summary outlines certain terms of the Bridge Facility referred to in the Commitment Letter, of which this Annex B is a part.  Certain capitalized terms used herein are defined in the Commitment Letter.
	
		
	Borrower:
	The Borrower under the Credit Agreement (the "Borrower").

	Guarantors:
	Each subsidiary of the Borrower that is or is required to be a guarantor under the Credit Agreement (the "Guarantors") will guarantee (the "Guarantee") all obligations of the Borrower under the Bridge Facility.  In addition, upon consummation of the Acquisition, the entity previously identified to the Arrangers as "Merlin" ("Target") and its subsidiaries that would otherwise become guarantors under the Credit Agreement will guarantee all obligations in respect of the Bridge Facility.

	Joint Lead Arranger and Joint Bookrunners:
	 
J.P. Morgan Securities LLC ("J.P. Morgan") in its capacity as Joint Lead Arranger and Joint Bookrunner, and each of Goldman Sachs Lending Partners LLC ("GSLP") and Royal Bank of Canada ("Royal Bank") in their capacities as Joint Bookrunners.

	Co-Documentation Agents:
	Each of GSLP, Royal Bank, Merrill Lynch, Pierce, Fenner & Smith Incorporated ("Merrill Lynch"), Morgan Stanley Senior Funding, Inc. ("Morgan Stanley"), Barclays Bank PLC ("Barclays"), SunTrust Bank ("SunTrust"), DNB Markets, Inc. ("DNB Markets") and The Bank of Nova Scotia ("BONS") in its capacity as Co-Documentation Agents (the "Co-Documentation Agents") (collectively, the "Bridge Lead Arrangers" or, the "Arrangers").

	Sole Syndication Agent:
	J.P. Morgan, in its capacity as Syndication Agent (the "Syndication Agent").

	Bridge Administrative Agent:
	JPMCB, in its capacity as Administrative Agent (the "Bridge Administrative Agent").

	Lenders:
	JPMCB, GSLP, Royal Bank, Bank of America, N.A. ("BOA"), Morgan Stanley, Barclays, SunTrust Bank ("SunTrust"), DNB Bank ASA ("DNB"), BONS and/or other financial institutions selected by the Bridge Lead Arrangers in consultation with Borrower (each, a "Lender" and, collectively, the "Lenders").

	Amounts of Bridge Loans:
	$2,750 million in aggregate principal amount of senior unsecured increasing rate loans, less the amount of gross proceeds from any sale of Securities received on or prior to the Closing Date (the "Bridge Loans").  A portion of the proceeds of the Bridge Loans may be placed in escrow subject to escrow arrangements reasonably satisfactory to the Bridge Lead Arrangers in order to settle obligations in respect of the Target Indentures (and settle related warrants) after the Closing Date in accordance with the terms thereof.

	Closing Date:
	The date on which Bridge Loans are made and the Acquisition is consummated (the "Bridge Closing Date").

Annex B-1    

	
		
	Ranking:
	The Bridge Loans, the Guarantee and all obligations with respect thereto will be senior unsecured obligations and rank pari passu in right of payment with all of the Borrower's and the Guarantors' existing and future senior obligations (including the obligations under the Credit Agreement).

	Maturity:
	The Bridge Loans will mature on the tenth anniversary of the Bridge Closing Date.  At any time and from time to time, on or after the first anniversary of the Bridge Closing Date, upon reasonable prior written notice and in a minimum principal amount of at least $100.0 million, the Bridge Loans may be exchanged (each such exchange, an "Exchange"), in whole or in part, at the option of the applicable Lender or Lenders, for senior unsecured exchange notes (the "Exchange Notes"), in a principal amount equal to the principal amount of the Bridge Loans so exchanged and having the same maturity date as the Bridge Loans so exchanged.  

	 
	The Exchange Notes will be issued pursuant to an indenture (the "Indenture") that will have the terms set forth on Exhibit 1 to this Annex B.

	Demand Failure Event:
	Any failure to comply with the terms of a Bridge Takeout Notice (as defined in the Fee Letter) for any reason will be deemed to be a "Bridge Takeout Demand Failure Event" (as defined in the Fee Letter) under the Bridge Facility Documentation.

	Interest Rate:
	Until the earlier of (i) the first anniversary of the Bridge Closing Date or (ii) the occurrence of a Bridge Takeout Demand Failure Event (such earlier date, the "Conversion Date"), the Bridge Loans will bear interest at a floating rate, reset quarterly, as follows:  (x) for the first three-month period commencing on the Bridge Closing Date, the Bridge Loans will bear interest at a rate per annum equal to the reserve adjusted Eurodollar Rate (subject to a reserve adjusted Eurodollar Rate Floor of 1.25% per annum), plus 612.5 basis points (collectively, the "Bridge LIBOR Rate") and (y) thereafter, interest on the Bridge Loans will be payable at a floating per annum rate equal to the interest rate applicable during the prior three-month period, in each case plus the Bridge Spread, reset at the beginning of each subsequent three-month period.  The "Bridge Spread" will initially be 50 basis points (commencing three months after the Bridge Closing Date) and will increase by an additional 50 basis points every three months thereafter.  Notwithstanding the foregoing, at no time will the per annum interest rate on the Bridge Loans exceed the Total Cap (as defined in the Fee Letter) then in effect (plus default interest, if any).

	 
	From and after the Conversion Date, the Bridge Loans will bear interest at a fixed rate equal to the Total Cap (plus default interest, if any).

	 
	Prior to the Conversion Date, interest will be payable at the end of each interest period.  Accrued Interest shall also be payable in arrears on the Conversion Date and on the date of any prepayment of the Bridge Loans.  From and after the Conversion Date, interest will be payable quarterly in arrears and on the date of any prepayment of the Bridge Loans.

Annex B-2    

	
		
	 
	As used herein, the term "reserve adjusted Eurodollar Rate" will have the meaning customary and appropriate for financings of this type, and the basis for calculating accrued interest and the interest periods for loans bearing interest at the reserve adjusted Eurodollar Rate will be customary and appropriate for financings of this type.

	 
	After the occurrence and during the continuance of an Event of Default, interest on all overdue amounts then outstanding will accrue at a rate equal to the applicable rate set forth above, plus an additional two percentage points (2.00%) per annum and will be payable on demand.

	Funding Protection:
	Customary for transactions of this type, including breakage costs, gross-up for withholding, compensation for increased costs and compliance with capital adequacy and other regulatory restrictions.

	Mandatory Prepayment:
	Prior to the Conversion Date and to the extent permitted by the Credit Agreement, the net proceeds to the Borrower, Parent or any subsidiary of Parent (including the Target) from (a) any direct or indirect public offering or private placement of any debt or equity securities (other than issuances pursuant to employee stock plans), (b) any future bank borrowings (except borrowings under the Credit Agreement) and (c) subject to certain ordinary course exceptions and reinvestment rights, any future asset sales or receipt of insurance proceeds will be used to repay the Bridge Loans, as a result of an asset sale or receipt of insurance proceeds, in each case at 100% of the principal amount of the Bridge Loans prepaid plus accrued interest to the date of prepayment.  Any proceeds from the sale of a Bridge Takeout Financing (as defined in the Fee Letter) funded or purchased by a Lender or one or more of its affiliates will be applied, first, to refinance the Bridge Loans held at that time by such Lender, and second, in accordance with the pro rata provisions otherwise applicable to prepayments.  

	 
	Nothing in these mandatory prepayment provisions will restrict or prevent any holder of Bridge Loans from exchanging Bridge Loans for Exchange Notes on or after the first anniversary of the Bridge Closing Date.

	Change of Control:
	Upon the occurrence of a Change of Control (to be defined), subject to the Credit Agreement, the Borrower will be required to prepay in full all outstanding Bridge Loans at par plus accrued interest to the date of prepayment, plus with respect to any Bridge Loans so prepaid on or after the Conversion Date, a 1.0% prepayment premium.  Prior to making any such prepayment, the Borrower will, within 30 days of the Change of Control, repay all obligations under the Credit Agreement or obtain any required consent of the lenders under the Credit Agreement to make such prepayment of the Bridge Loans.  From and after the Conversion Date, each holder of Bridge Loans may elect to accept or waive a prepayment such holder is otherwise entitled to receive pursuant to this paragraph.

	Voluntary Prepayment:
	Prior to the Conversion Date, Bridge Loans may be prepaid, in whole or in part, at the option of the Borrower, at any time (except as provided below) without premium or penalty, upon five business days' written notice, such prepayment to be made at par plus accrued interest.

Annex B-3    

	
		
	 
	Subject to the next paragraph, from and after the Conversion Date and prior to the tenth anniversary of the Bridge Closing Date, Bridge Loans may be prepaid, in whole or in part, at the option of the Borrower, at any time (except as provided below) upon 3 days' prior written notice at par plus accrued interest to the date of repayment plus the Applicable Premium.  The "Applicable Premium" will be (i) a make-whole premium based on the applicable treasury rate plus 50 basis points prior to the fifth anniversary of the Bridge Closing Date, (ii) one-half of the then-prevailing interest rate on the Bridge Loans from and including the fifth anniversary of the Bridge Closing Date to and including the sixth anniversary of the Bridge Closing Date and (iii) declining to one-quarter of the then-prevailing interest rate on the Bridge Loans on the sixth anniversary of the Bridge Closing Date, to one-eighth of the then-prevailing interest rate on the Bridge Loans on the seventh anniversary of the Bridge Closing Date and to zero on the eighth anniversary of the Bridge Closing Date.

	Security:
	None.

	Bridge Facility Documentation:
	The Facility Documentation for the Bridge Facility (the "Bridge Facility Documentation") shall be negotiated in good faith, shall contain the terms and conditions set forth in this Annex B and shall be based on the terms of the Credit Agreement and the Existing Indentures (as defined in Annex C) and will take into account the terms set forth in the Commitment Letter, current market conditions and differences related to your business since the date of the Credit Agreement and the Existing Indentures, with such customary changes to reflect the interim nature of the Bridge Facility (collectively, the "Bridge Documentation Principles").  The Bridge Facility Documentation shall contain only those payments, conditions to borrowing, mandatory prepayments, representations and warranties, covenants and events of default expressly set forth in this Annex B, in each case applicable to Parent, the Borrower and their restricted subsidiaries and with standards, definitions, qualifications, thresholds, exceptions, "baskets" and grace periods consistent with the Bridge Documentation Principles.

	Representations and Warranties:
	The Bridge Facility Documentation will contain representations and warranties consistent with the Credit Agreement with changes as are usual and customary for financings of this kind, consistent with the Bridge Documentation Principles.

	Covenants:
	The Bridge Facility Documentation will contain the following covenants:  (a) affirmative covenants consistent with the Credit Agreement with changes as are usual and customary for financings of this kind, consistent with the Bridge Documentation Principles; (b) incurrence-based negative covenants consistent with the Credit Agreement, with changes as are usual and customary for financings of this kind consistent with the Bridge Documentation Principles; provided that prior to the Conversion Date, the restricted payments and debt incurrence covenants in the Bridge Facility Documentation shall be more restrictive.  There will not be any financial maintenance covenants in the Bridge Facility Documentation.  

	 
	The Bridge Facility Documentation will contain a covenant requiring the Borrower to comply with the terms of the Fee Letter, including any Take-out Notice (as defined in the Fee Letter) and any cooperation required in connection therewith.

Annex B-4    

	
		
	Events of Default:
	The Bridge Facility Documentation will contain such events of default as are consistent with the Credit Agreement with changes as are usual and customary for financings of this kind, consistent with the Bridge Documentation Principles.

	Conditions Precedent to Borrowing:
	The several obligations of the Lenders to make, or cause one of their respective affiliates to make, the Bridge Loans will be subject to (i) the conditions precedent referred to in Section 2 of the Commitment Letter and those listed on Annex C attached to the Commitment Letter and (ii) prior written notice of borrowing.

	Assignments and Participations:
	Each of the Lenders may assign all or (subject to minimum assignment amount requirements) any part of its Bridge Loans to its affiliates (other than natural persons) or one or more banks, financial institutions or other entities that are "Eligible Assignees," as defined in the Bridge Facility Documentation, that are reasonably acceptable to the Bridge Administrative Agent, such consent not to be unreasonably withheld or delayed.

	 
	Upon such assignment, such Eligible Assignee will become a Lender for all purposes under the Bridge Facility Documentation; provided that assignments made to affiliates and other Lenders will not be subject to the above described consent or any minimum assignment amount requirements.  A $3,500 processing fee will be required in connection with any such assignment.  The Lenders will also have the right to sell participations, subject to customary limitations on voting rights, in their respective Bridge Loans.

	Requisite Lenders:
	Lenders holding at least a majority of total Bridge Loans, with certain amendments requiring the consent of Lenders holding a greater percentage (or all) of the total Bridge Loans.

	Taxes:
	The Bridge Facility Documentation will include tax gross-up, cost and yield protection provisions substantially similar to those provisions for tax gross-up, cost and yield protection contained in the Credit Agreement.

	Indemnities:
	The Bridge Facility Documentation will provide customary and appropriate provisions relating to indemnity and related matters in a form reasonably satisfactory to the Bridge Lead Arrangers, the Bridge Administrative Agent and the Lenders.

	Governing Law and Jurisdiction:
	The Bridge Facility Documentation will provide that the Borrower will submit to the exclusive jurisdiction and venue of the federal and state courts of the State of New York and will waive any right to trial by jury.  New York law will govern the Bridge Facility Documentation.

	Counsel to the Bridge Lead Arrangers and the Bridge Administrative Agent:
	 
 
Cahill Gordon & Reindel LLP.

The foregoing is intended to summarize certain basic terms of the Bridge Loans.  It is not intended to be a definitive list of all of the requirements of the Lenders in connection with the Bridge Loans.

Annex B-5    

Exhibit 1 to Annex B
Summary of Exchange Notes
This Summary of Exchange Notes outlines certain terms of the Exchange Notes referred to in Annex B to the Commitment Letter, of which this Exhibit 1 is a part.  Capitalized terms used herein have the meanings assigned to them in Annex B to the Commitment Letter.
Exchange Notes
At any time on or after the first anniversary of the Bridge Closing Date, upon not less than five business days' prior notice, Bridge Loans may, at the option of a Lender, be exchanged for a principal amount of Exchange Notes equal to 100% of the aggregate principal amount of the Bridge Loans so exchanged.  At a Lender's option, Exchange Notes will be issued directly to its broker-dealer affiliate or other third party designated by it, upon surrender by the Lender to the Borrower of an equal principal amount of Bridge Loans.  No Exchange Notes will be issued until the Borrower receives requests to issue at least $100 million in aggregate principal amount of Exchange Notes.  The Borrower will issue Exchange Notes under an indenture (the "Indenture") that complies with the Trust Indenture Act of 1939, as amended.  The Borrower will appoint a trustee reasonably acceptable to the Lenders.  

Annex B-1-1

	
		
	Final Maturity:
	Same as Bridge Loans.

	Interest Rate:
	Each Exchange Note will bear interest at a fixed rate equal to the Total Cap then in effect (plus default interest, if any).  Interest will be payable semiannually in arrears.

	 
	Additional default interest on all amounts outstanding will accrue at the applicable rate plus two percentage points (2.00%) per annum.

	Optional Redemption:
	The Exchange Notes may be redeemed, in whole or in part, at the option of the Borrower, at any time (except as provided below) upon 3 days' prior written notice at par plus accrued interest to the date of repayment plus the Applicable Premium.  The "Applicable Premium" will be (i) a make-whole premium based on the applicable treasury rate plus 50 basis points prior to the fifth anniversary of the Bridge Closing Date, (ii) one-half of the Total Cap from and including the fifth anniversary of the Bridge Closing Date to and including the sixth anniversary of the Bridge Closing Date and (iii) declining to one-quarter of the Total Cap on the sixth anniversary of the Bridge Closing Date, to one-eighth of the Total Cap on the seventh anniversary of the Bridge Closing Date and to zero on the eighth anniversary of the Bridge Closing Date.

	 
	In addition, prior to the third anniversary of the Bridge Closing Date, up to 35% of the original principal amount of the Exchange Notes may be redeemed from the proceeds of a qualifying equity offering by the Borrower at a redemption price equal to par plus the Total Cap and accrued interest.

	Defeasance Provisions of Exchange Notes:
	Customary.

	Modification:
	Customary.

	Change of Control:
	Customary at 101%.

	Registration Rights:
	None.

	Covenants:
	The Indenture will include covenants similar to those contained in an indenture governing publicly traded high yield debt securities; provided that the Exchange Note covenants may be more restrictive in certain respects giving due regard to, among other things, then existing market conditions.

	Events of Default:
	The Indenture will provide for Events of Default similar to those contained in an indenture governing publicly traded high yield debt securities giving due regard to, among other things, then existing market conditions.

The foregoing is intended to summarize certain basic terms of the Exchange Notes.  It is not intended to be a definitive list of all of the requirements of the Lenders in connection with the Exchange Notes
.

Annex B-1-2

Annex C
Summary of Conditions Precedent to the Facility
This Summary of Conditions Precedent outlines the conditions precedent to the Facility referred to in the Commitment Letter, of which this Annex C is a part.  Certain capitalized terms used herein are defined in the Commitment Letter.
		
	A.
	The conditions to and the initial funding under the Bridge Facility shall consist of the following (together with any other conditions to funding expressly set forth in Section 2 of the Commitment Letter):

1.    Acquisition:  The terms of the Acquisition Agreement will be reasonably satisfactory to the Arrangers; provided that the Arrangers acknowledge that the Acquisition Agreement dated as of September 2, 2012 is reasonably acceptable to the Arrangers.  No conditions precedent to the consummation of the Acquisition or other provision in the Acquisition Agreement dated as of September 2, 2012 shall have been waived, modified, supplemented or amended (and no consent granted), in a manner materially adverse to the Arrangers or the Lenders in their capacities as Lenders, in each case without the consent of the Arrangers, not to be unreasonably withheld or delayed (provided that, without limitation, (i) any decrease in the Acquisition consideration of not more than 10% that is not accompanied by a corresponding dollar-for-dollar reduction in the amount of the Bridge Loans (it being understood and agreed that a reduction of less than 10% in the Acquisition consideration that is accompanied by a dollar-for-dollar reduction in the amount of the Bridge Loans shall not be deemed materially adverse to the Arrangers or the Lenders) or (ii) any decrease in the Acquisition consideration in excess of 10%, shall in each case be deemed to be materially adverse and require the consent of the Arrangers).  
2.    Concurrently with the consummation of the Acquisition and after giving effect to the financing thereof,  all material indebtedness outstanding of Parent, the Company and their respective subsidiaries, including the Target, (other than (i) the Bridge Loans as contemplated by the Commitment Letters and/or any Securities issued in lieu thereof, (ii) indebtedness under the Credit Agreement and the Existing Indentures, (iii) notes issued under the Target Indentures, to the extent the holders thereof have not converted such notes or exercised their option to require the Target to repurchase such notes and (iv) trade payables and other ordinary course or similar obligations) shall have been repaid or repurchased in full, all commitments relating thereto shall have been terminated, and all liens or security interests related thereto shall have been terminated or released, in each case on terms reasonably satisfactory to the Arrangers and subject to exceptions to be mutually agreed upon.  For purposes of this Annex C (and the Commitment Letter to which this Annex C forms a part), the "Existing Indentures" shall mean the Indenture, dated as of September 28, 2010, among the Borrower, Parent, The Bank of New York Mellon Trust Company, N.A., as trustee, and the Guarantors listed therein; the Indenture, dated as of November 23, 2010, among the Borrower, Parent, The Bank of New York Mellon Trust Company, N.A., as trustee, and the Guarantors listed therein; the Indenture, dated as of February 8, 2011, among the Borrower, Parent, The Bank of New York Mellon Trust Company, N.A., as trustee, and the Guarantors listed 

Annex C-1

therein; and the Indenture, dated as of March 8, 2011, among the Borrower, Parent, The Bank of New York Mellon Trust Company, N.A., as trustee, and the Guarantors listed therein.
3.    The Arrangers shall have received (i) audited financial statements of the Company and Target for each of the three fiscal years immediately preceding the initial funding ended more than 90 days prior to the Closing Date; (ii) unaudited financial statements of the Company and the Target for any fiscal quarter ended after the date of the most recent audited financial statements of such person and more than 45 days prior to the Closing Date; and (iii) customary pro forma financial statements, in each case meeting the requirements of Regulation S-X for a Form S-1 registration statement (other than Rules 3-10 and 3-16 of Regulation S-X).
4.    All costs, fees, expenses (including, without limitation, reasonable and invoiced (at least two days prior to the Closing Date) out-of-pocket legal fees and expenses, title premiums, survey charges and recording taxes and fees) and other compensation contemplated by the Commitment Letter and the Fee Letter payable to the Commitment Parties, the Arrangers, the Administrative Agent, the Bridge Administrative Agent or the Lenders on the Closing Date shall have been paid to the extent due and Parent and the Company shall have complied in all material respects with all of their respective obligations under the Commitment Letter and the Fee Letter.
5.    The Arrangers shall be satisfied that the Company and Parent have complied with the following closing conditions and delivered the following customary documentation relating to the Borrower and all of the Guarantors (including Parent):  (i) the delivery of customary legal opinions, corporate records and documents from public officials, lien searches and officer's certificates as to the Borrower and each of the Guarantors; (ii) evidence of authority; and (iii) delivery of a solvency certificate from the chief financial officer of the Borrower in form and substance, and with supporting documentation, reasonably satisfactory to the Arrangers, as to the Borrower, Parent and the Guarantors on a consolidated basis.  The Specified Representations and the Specified Acquisition Agreement Representations shall be true and correct in all material respects.
6.    The Arrangers will have received at least 5 days prior to the Closing Date all documentation and other information required by bank regulatory authorities under applicable "know-your-customer" and anti-money laundering rules and regulations, including the Patriot Act, to the extent requested at least 10 days prior to the Closing Date.
7.    The Arrangers and one or more Investment Banks each shall have received no later than 20 consecutive calendar days prior to the Closing Date (provided that the days from November 21, 2012 through November 25, 2012 shall not be considered calendar days for such purpose and if such period has not ended prior to December 20, 2012, such period shall be deemed not to have commenced until January 2, 2013) a customary offering memorandum containing all customary information, including financial statements, pro forma financial statements, business and other financial data of the type required in a registered offering of debt securities by Regulation S-X and Regulation S-K under the Securities Act (other than Rules 3-10 and 3-16 of 

Annex C-2

Regulation S-X and subject to exceptions customary for private placements pursuant to Rule 144A promulgated under the Securities Act) or that would be necessary for the Investment Bank to receive customary (for high yield debt securities) "comfort" (including "negative assurance" comfort) from independent accountants in connection with the offering of the Securities, and, in the case of the annual financial statements, the auditors' reports thereon, and concurrently with the time period provided for above, the Investment Bank shall have had a period of at least 20 consecutive calendar days following delivery of the offering memorandum to market the Notes (the "Marketing Period").

Annex C-3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]